FDA’s Orphan Exclusivity Requirement For “Clinical Superiority” Challenged In Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Depomed argues in a suit against FDA that it should not have to show Gralise (gabapentin) is clinically superior to Neurontin since Neurontin never received an orphan drug designation or orphan exclusivity.